LIXT vs. SNGX, BIOR, FBRX, MEIP, NRBO, VINC, INDP, LUMO, SNSE, and IBIO
Should you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include Soligenix (SNGX), Biora Therapeutics (BIOR), Forte Biosciences (FBRX), MEI Pharma (MEIP), NeuroBo Pharmaceuticals (NRBO), Vincerx Pharma (VINC), Indaptus Therapeutics (INDP), Lumos Pharma (LUMO), Sensei Biotherapeutics (SNSE), and iBio (IBIO). These companies are all part of the "pharmaceutical preparations" industry.
Lixte Biotechnology (NASDAQ:LIXT) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, community ranking, analyst recommendations, valuation, profitability, earnings, dividends and risk.
Lixte Biotechnology has a beta of -0.23, indicating that its share price is 123% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500.
Lixte Biotechnology has higher earnings, but lower revenue than Soligenix. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.
Lixte Biotechnology has a net margin of 0.00% compared to Soligenix's net margin of -1,025.66%. Soligenix's return on equity of -198.36% beat Lixte Biotechnology's return on equity.
5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 15.5% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 1.4% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Soligenix received 278 more outperform votes than Lixte Biotechnology when rated by MarketBeat users.
In the previous week, Soligenix had 3 more articles in the media than Lixte Biotechnology. MarketBeat recorded 6 mentions for Soligenix and 3 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 1.59 beat Soligenix's score of 0.68 indicating that Lixte Biotechnology is being referred to more favorably in the media.
Soligenix has a consensus price target of $3.00, suggesting a potential upside of 729.88%. Given Soligenix's higher possible upside, analysts clearly believe Soligenix is more favorable than Lixte Biotechnology.
Summary
Soligenix beats Lixte Biotechnology on 9 of the 14 factors compared between the two stocks.
Get Lixte Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lixte Biotechnology Competitors List
Related Companies and Tools
